(TSX Venture: ARI) TORONTO, Dec. 6 /CNW/ - ARIUS Research Inc. (TSX-V - ARI) is pleased to announce that it has been selected as one of the 2005 TSX Venture 50, a ranking of the top 50 public venture capital companies listed on the TSX Venture Exchange. The project was initiated by the Exchange with PROFIT Magazine to highlight quality Canadian companies that are using public venture capital to achieve growth. The criteria used to compile the list include revenue, return on investment, market capitalization growth and trading volume. The inaugural TSX Venture 50 will be published in the following publications: - PROFIT Magazine (December issue) - Canadian Business Magazine (December 26 issue) - L'ActualitDe (February issue) "There are over 2000 companies on the TSX Venture Exchange and we are honoured to be included among the Top 50," said Dr. David S. Young, President and Chief Scientific Officer of ARIUS. "There is a broad consensus that biotechnology is an important area of growth for the Canadian economy. An example of its increasing prominence is the recent creation of the Ministry of Research and Innovation in Ontario. We believe that companies such as ours have an important mission to advance the health and welfare of Canadians. We thank the TSXV for this timely recognition of our technology, our business strategy and our potential for growth in this important area of commercial endeavour." About ARIUS Research ARIUS Research Inc. is a biotechnology company dedicated to the discovery and development of novel anticancer monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs targeting a variety of cancer indications. This antibody generation engine has enabled ARIUS to assemble a growing pipeline of over 300 functional MAbs, which may be used for commercial collaborations, out-licensing or in-house development. ARIUS has ongoing licensing and research partnerships with key biotechnology and drug development companies that provide revenues and access to external technologies. The long-term vision of ARIUS is to deliver personalized therapy by matching multiple antibodies to the distinct antigenic characteristics of each patient's tumor cells thereby increasing efficacy and avoiding side effects. Forward-Looking Statement Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in the Company's Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments. Website: www.ariusresearch.com The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.